Doximity (DOCS) Q1 2027 earnings review
Top-Line Stabilization Hides A Steep AI Price Tag
Doximity's fiscal 2027 kicked off exactly as management previously warned: an 'AI Investment Year' that sacrifices near-term profitability for platform growth. Revenue grew a modest but accelerating 7% YoY to $156.6M, beating the company's own guidance. However, the costs to build and scale its clinical AI assistant, Doximity Ask, are severely depressing the bottom line. GAAP Net Income plummeted 54% YoY to $24.3M, and Adjusted EBITDA margins compressed to 47.7% from 54.7%. While management slightly raised full-year revenue targets, they simultaneously cut the EBITDA outlook, confirming that the cost of AI leadership is running hotter than initially planned.
🐂 Bull Case
Physicians are flocking to the new tools. Workflow active prescribers jumped over 30% YoY, and AI Search queries grew 25% sequentially. The core network moat remains fully intact.
Despite a soft macro backdrop for pharma ad spending, Q1 revenue beat the top end of guidance, prompting management to raise the full-year revenue target midpoint by $6M.
🐻 Bear Case
The margin degradation is severe. GAAP net income halved YoY, dragged down by a massive 68% spike in stock-based compensation and a 43% surge in R&D expenses.
Guidance for Q2 implies revenue of ~$170.5M, which translates to a meager 1% YoY growth against a tough prior-year comparison, highlighting sluggish pharma budget deployment.
⚖️ Verdict: ⚪
Neutral. Doximity is successfully defending its market share and driving record physician engagement with its AI tools. However, the escalating costs required to build this technology—evidenced by the full-year EBITDA guidance cut—means investors must endure a painful earnings contraction before the AI monetization thesis proves itself.
Key Themes
Doximity Ask Emerges as Best-in-Class (Tech Innovation)
Management highlighted that its clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark. This technical validation is translating directly into usage: AI Search query volume is accelerating, growing over 25% quarter-over-quarter. This engagement serves as the foundation for the company's new AI monetization strategy targeting pharma search budgets.
Revenue Beat Contradicted by EBITDA Guidance Cut
Doximity beat Q1 revenue guidance by ~$5M and subsequently raised its full-year revenue outlook by $6M at the midpoint. Normally, in a software model, this top-line outperformance flows to the bottom line. Contradicting this narrative, management actually cut the full-year Adjusted EBITDA midpoint by $10M. This indicates that AI compute and personnel costs are scaling faster than anticipated, completely erasing the benefits of operating leverage.
Q2 Guidance Exposes Macro Softness
The implied Q2 revenue growth is decelerating violently to just ~1.2% YoY (guidance midpoint of $170.5M vs $168.5M in 26Q2). While management previously noted that 26Q2 benefited from an irregular pull-forward of upsell dollars, this flat trajectory confirms that the broader HCP digital pharma advertising market remains soft and clients continue to delay large, long-term budget commitments.
Core Workflow Engagement Reaches New Highs
Despite the financial noise, the underlying network health is excellent. The number of unique active prescribers using Doximity's workflow tools grew by more than 30% YoY. As long as doctors remain glued to the platform for daily tasks (calling, scheduling, AI scribing), Doximity maintains the premium attention necessary to command high advertising rates.
Stock-Based Compensation Out of Control
A massive driver of the 54% drop in GAAP Net Income is the explosion in Stock-Based Compensation (SBC). SBC surged 68% YoY to $36.8M for the quarter, consuming 23.5% of total revenue. Management is attempting to offset this dilution via aggressive share repurchases, but this level of equity issuance drastically lowers the true profitability of the enterprise.
Other KPIs
Reversing sharply. FCF dropped 34% YoY from $60.1M in 26Q1, closely mirroring the decline in operating profitability. While the cash generation remains positive, the reduced cash flow limits the company's ability to seamlessly fund both aggressive share repurchases and heavy M&A moving forward.
Stable. Total cash, equivalents, and marketable securities stand at a healthy ~$688M. Despite spending $91.6M on share repurchases in the quarter, the balance sheet remains a fortress, providing ample runway for the 'AI Investment Year' without needing outside capital.
Guidance
Decelerating. The midpoint of $170.5M implies YoY growth of just ~1.2% against a difficult Q2 FY26 comparison ($168.5M). It suggests that the highly anticipated release of delayed pharma budgets has not yet fully materialized.
Decelerating. Implies a margin of roughly 47.5%. Down materially from the $100.8M (60% margin) generated in the prior-year quarter, emphasizing the structural step-up in base operating costs.
Accelerating slightly. The midpoint of $676M represents a $6M raise from the prior guidance issued three months ago. It implies a full-year growth rate of approximately 4.8% over FY26.
Decelerating. In a negative twist, the midpoint was lowered by $10M (from a prior midpoint of $329M to $319M), despite the revenue raise. Implies full-year margins will compress to ~47%, down from 55% in FY26.
Key Questions
EBITDA Guidance Cut Dynamics
You raised full-year revenue but lowered the EBITDA target. What specific cost line items (compute, R&D headcount, marketing) are running hotter than you expected just 90 days ago?
Pharma Budget Visibility
Q2 guidance implies barely 1% YoY revenue growth. Are you seeing concrete evidence that the delayed calendar 2026 pharma budgets will finally unlock in the fiscal second half, or is the market remaining in a 'wait-and-see' holding pattern?
AI Search Monetization Timeline
With AI Search queries growing 25% sequentially and Doximity Ask performing well in benchmarks, when do you expect the 'med-legal reviews' at major pharma clients to clear and allow this product to become a material revenue contributor?
Managing SBC Dilution
Stock-based compensation has ballooned to 23.5% of revenue. Is this the peak run-rate for SBC as you digest the Pathway acquisition and AI talent grants, or should we expect this elevated percentage to persist into FY28?